Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Herzuma, biosimilar of Herceptin, not on market yet
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Mar 29, 2014 02:28:43
It is unclear when Celltrion’s Herzuma, the biosimilar of Herceptin, will be put on the market as Roche;s patent infringement case for its Herceptin is still pending.

Herzuma got approved by the Ministry of Food and Drug Safety on January 15, 2014. Roche filed the lawsuit immediately after the marketing approval and Celltrion also filed its case to invalidate Roche’s action. Roche still has one patent good until 2017 for Herceptin.

Herceptin sales were 86.2 billion won last year according to IMS Health Data. It was ranked No. 3 after Baraclude and Lipitor by prescription sales.

Herceptin costs 520,000 won per 150mg injection. Cancer patients pay 5% of the total cost of drug therapies. Herzuma price is 30% lower than Herceptin’s.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com